Upfront Radiotherapy Combined With Almonertinib for Brain Metastasis in Non-small Cell Lung Cancer With EGFR Mutation: A Prospective Single-arm Phase II Trial
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Aumolertinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Aug 2022 Planned number of patients changed from 47 to 37 according to trial design presented at the 2022 World Conference on Lung Cancer
- 09 Aug 2022 Status changed from not yet recruiting to recruiting according to trial design presented at the 2022 World Conference on Lung Cancer
- 09 Aug 2022 Trial design presented at the 2022 World Conference on Lung Cancer